Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2023 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's own repeatable business is escalating. We need to look for management's own words that indicate a comparison against the company's own recent past, that it's already real and recurring, and that it's early. Let's review the transcript. The call is about Q1 fiscal 2023 results. Management discusses revenue decline, but also mentions growth in direct-to-consumer, lab-grown diamonds, etc. However, the question is specifically about whether the deals, orders, contracts, projects, customers, sites, or programs are individually larger, broader, or longer than before. Looking through the transcript, there is no mention of deal sizes, order sizes, contract values, or any such escalation. Management talks about revenue, inventory, marketing, product launches, but nothing about the size of individual engagements increasing. They mention that they are expanding product categories, but that's not about the size of each deal. They talk about opening a showroom, but that's not about successive engagements. The only possible hint is when they talk about lab-grown diamond revenues increasing 85% year-over-year, but that's revenue growth, not necessarily larger individual deals. They also mention that they are expanding collections and assortments, but again, that's about product breadth, not unit size. There is no mention of "larger orders," "bigger contracts," "customers starting at higher levels," etc. The management does not convey any escalation in the size of what they land. They talk about softening demand, reducing forecasts, etc. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.